Resverlogix entered agreement with Supreme Council of Arab-African Economy for development of Apabetalone for COVID-19 patients
On Nov. 5, 2021, Resverlogix announced that it had entered into a cooperation agreement with the Supreme Council…
-
-
Novavax filed COVID-19 vaccine for provisional approval in New Zealand
On Nov. 3, 2021, Novavax announced the company had filed for provisional approval of the vaccine to the…
-
NRx Pharmaceuticals announced favorable safety report for ZYESAMIﾮ (aviptadil) in critical care study in patients with COVID-19
On Nov. 5, 2021, NRx Pharmaceuticals reported a safety update on ZYESAMIﾮ (aviptadil), which was being tested in…
-
U.S. FDA authorizd InteliSwabﾙ COVID-19 rapid tests for at-home testing for delta variant detection
On Nov. 2, 2021, OraSure Technologies announced that the EUA for its InteliSwabﾙ COVID-19 rapid tests had been…
-
NIH announced study of long-term effects of COVID-19 in pregnancy
On Nov. 2, 2021, the National Institutes of Health announced support for a four-year follow-up study on the…
-
FDA cleared the first 510(k) for a COVID-19 test, the BioFire COVID-19 Test 2
On Nov. 1, 2021, the U.S. Food and Drug Administration (FDA) cleared the first 510(k) for a COVID-19…
-
Novavax filed for COVID-19 vaccine authorization with Health Canada and completed submission to EMA
On Nov. 1, 2021, Novavax announced the completion of its rolling submission to Health Canada for authorization of…
-
TGen case study documented first reported U.S. transmission of COVID from a pet owner to pets
On Nov. 1, 2021, for the first time in the U.S., the transmission of COVID-19 from pet parent…
-
Novavax and Serum Institute of India receive Emergency Use Authorization for COVID-19 vaccine in Indonesia
On Nov. 1, 2021, Novavax and Serum Institute of India announced that the National Agency of Drug and…
-
Moderna updated timing of U.S. Emergency Use Authorization of its COVID-19 vaccine for adolescents
On Oct. 31, 2021, Moderna announced that the U.S. Food and Drug Administration (FDA) had notified the Company…
-
Penn Medicine Pavilion opened to patients
On Oct. 30, 2021, Penn Medicine officially opened the doors of its 1.5 million-square-foot future-ready Pavilion as clinical…
-
NIH researchers identified how two people controlled HIV after stopping treatment
On Oct. 29, 2021, research led by scientists at the National Institutes of Health announced they had identified…
-
CDC | COVID-19 | Diagnostics | Vaccine
U.S. CDC study showed vaccination offered higher protection than previous COVID-19 infection
On Oct. 29, 2021, the Centers for Disease Control and Prevention (CDC) published “new science” reinforcing that vaccination…
-
Oregon Health & Science University moved forward with hospital expansion
On Oct. 29, 2021, Oregon Health & Science University’s (OHSU) board of directors approved a project to expand…
-
Novavax filed for provisional approval of its COVID-19 vaccine in Australia
On Oct. 29, 2021, Novavax announced the completion of its rolling submission to the Therapeutic Goods Administration (TGA)…
-
Pfizer and BioNTech received first U.S. FDA EUA of COVID-19 vaccine in children ages 5 through 11 years
On Oct. 29, 2021, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) had authorized…
-
Pfizer and BioNTech provided U.S. Government an additional 50 million pediatric doses of COVID-19 vaccine
On Oct. 28, 2021, Pfizer and BioNTech announced that the U.S. government had purchased 50 million more doses…
-
Relief Therapeutics reported positive interim data from trial of novel nasal spray Sentinox in SARS-CoV-2 infected patients
On Oct. 27, 2021, RELIEF THERAPEUTICS announced that its wholly owned subsidiary, APR Applied Pharma Research, reported positive…
-
Merck and MPP announced agreement for Molnupiravir, investigational oral antiviral COVID-19 medicine, to low- and middle-income countries
On Oct. 27, 2021, the Medicines Patent Pool (MPP) and Merck announced a voluntary licensing agreement to facilitate…
-
Monoclonal antibody treatment highly effective at reducing COVID-19 hospitalizations
On Oct. 27, 2021, researchers published interim results in The New England Journal of Medicine from a Phase…
-
Novavax filed for authorization of its COVID-19 vaccine in the United Kingdom
On Oct. 27, 2021, Novavax announced the completion of its rolling regulatory submission to the U.K. Medicines and…
-
Fulgent Genetics launched at-home neutralizing antibody test for COVID-19
On Oct. 27, 2021, Fulgent Genetics announced that it had launched an antibody test for COVID-19 which specifically…
-
Hologic’s Multiplex COVID-19/Flu Test became commercially available in North America and Europe
On Oct. 27, 2021, Hologic announced that its Aptima SARS-CoV-2/Flu Assay was available for the simultaneous detection and…
-
BioNTech planned to initiate construction of an mRNA vaccine manufacturing facility in Africa in mid-2022
On Oct. 26, 2021, BioNTech announce that the Company planned to initiate the construction of the first state-of-the-art…
-
FDA Advisory Committee votes in favor of granting EUA for Pfizer-BioNTech Covid-19 vaccine in children 5 to <12 years
On Oct. 26, 2021, Pfizer and BioNTech announced that the U.S. Food and Drug Administrationﾒs (FDA) Vaccines and…
-
Biotechnology | Diagnostics | Disease | Oncology | Vaccine | Women's Health
Anixa Biosciences announced patient dosing of investigational vaccine candidate in first-of-its-kind preventative breast cancer vaccine study
On Oct. 26, 2021, Anixa Biosciences announced that, in conjunction with its partner, Cleveland Clinic, it had commenced…
-
Moderna announced Swissmedic authorized booster dose of Moderna’s COVID-19 vaccine
On Oct. 26, 2021, Moderna announced that Swissmedic had authorized a booster dose of Spikevax, the Company’s vaccine…
-
Moderna announced MOU to supply up to 110 million doses of Its COVID-19 vaccine to the African Union
On Oct. 26, 2021, Moderna announced a new Memorandum of Understanding (MoU) to make up to 110 million…
-
Axcella Therapeutics launched clinical program to develop treatment for patients with long COVID
On Oct. 26, 2021, Axcella Therapeutics announced a new clinical program to investigate AXA1125 as a potential treatment…
-
Vaxart dosed first subject in phase II COVID-19 oral tablet vaccine clinical trial
On Oct. 26, 2021, Vaxart announced that it has dosed the first subject in its Phase II COVID-19…
